Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update


FOREX INVESSTORS  PRESS RELEASE  Acreage Pharms Ltd   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that its licensed production facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), Acreage Pharms Ltd. (“Acreage Pharms”) located near Edson, Alberta, utilizing a multi-room indoor perpetual growing methodology, will begin its first harvest the first week of August, with the second harvest occurring the following week.  The company anticipates a harvest to take place approximately monthly going forward.

Invictus MD is further pleased to announce that Acreage Pharms has received its development permit for Phase 2 and has broken ground initiating construction on its 27,800 square foot purpose built, multiple room production facility. All contractors and suppliers necessary for the project have been scheduled. Invictus MD has committed to investing $6.0 million, which will be used to fund the costs of constructing the production facility.

“Following our successful harvest at the AB Laboratories production facility as announced earlier, and by securing the development permit for our Alberta production facility, with $30 million cash available and the majority earmarked for building production capacity, Invictus MD is prepared for an exciting year of growth,” said Dan Kriznic, Executive Chairman and CEO, Invictus MD. “Led by one of the industry’s most experienced teams, we are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, our large land package allows for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy, and further establishing our leadership position as Canada’s cannabis company” added Kriznic.

Acreage Pharms Ltd

Invictus MD also announced that Mr Paul Sparkes and Mr. Josef W. Hocher have been appointed to the Company’s Board of Directors.

Mr. Paul Sparkes is an accomplished business leader with over twenty five years’ experience in media, public affairs, venture capital, and Canada’s political arena. He is Currently President of Otterbury Holdings Inc., a corporation advising growth companies in the private and public markets.  Most recently Mr. Sparkes was Executive Vice Chair, Director and co-founder of Difference Capital Financial, a TSX-listed specialty finance company. Previously, Mr. Sparkes was Executive Vice President, Corporate Affairs for CTVglobemedia (now Bellmedia). Prior to joining Bell Globemedia in 2001 as Group Vice-President, Public Affairs, Mr. Sparkes held senior positions in public service, including with the Government of Canada and the Government of Newfoundland and Labrador. From 1996 to 2001, he served in the Office of the Prime Minister of Canada as Director of Operations, and Special Assistant for Atlantic Canada. Mr. Sparkes also served as Executive Assistant to two Premiers of Newfoundland and Labrador. Mr. Sparkes sits on several public and private boards including Thunderbird Entertainment (private), Bluedrop Performance Learning Inc. (TSXV: BPL), Antler Gold Inc (TSXV:ANTL.V) BlastGard International Inc (BLGA-US) and is a former board member of the Liquor Control Board of Ontario ( LCBO).

Mr. Josef W. Hocher was a founder of Buried Hill Energy, an international oil and gas company, where he acted as co-chief executive in creating, developing and implementing the organization’s strategic direction.  He continues to serve as the Senior Independent Director and is also either a Chair or a member of various committees. Mr. Hocher also founded Hitic Energy Ltd., and was a partner at Osler, Hoskin & Harcourt LLP. He currently serves as Chairman of Orthoshop Geomatics Ltd., a geomatics services company; holds the position of Chief Commercial Officer at Field Upgrading Limited and Western Hydrogen Limited and since 2016, has been a Partner at Cassels, Brock & Blackwell LLP.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR, including its wholly owned subsidiary Acreage Pharms Ltd., as well as its investment in the fully licensed facility AB Laboratories Inc.; and Fertilizer and Nutrients through Future Harvest Development Ltd.

For more information, please visit

On Behalf of the Board,
Dan Kriznic
Executive Chairman & CEO

Larry Heinzlmeir
Vice President, Marketing & Communications

Cautionary Note Regarding Forward-Looking Statements: Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward Looking Information includes, but is not limited to, disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action; and the plans for completion of the Offering, expected use of proceeds and business objectives. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “anticipates”, “expects”, “understanding”, “has agreed to” or variations of such words and phrases or statements that certain actions, events or results “would”, “occur” or “be achieved”. Although Invictus has attempted to identify important factors that could affect Invictus and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended, including, without limitation, the risks and uncertainties related to the Offering not being completed in the event that the conditions precedent thereto are not satisfied. In making the forward-looking statements in this news release, Invictus has applied several material assumptions, including the assumptions that (1) the conditions precedent to completion of the Offering will be fulfilled so as to permit the Offering to be completed on or about June 1, 2017; (2) all necessary approvals will be obtained in a timely manner and on acceptable terms; and (3) general business and economic conditions will not change in a materially adverse manner. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Invictus does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Like up on FACEBOOK


Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

mCig Announces 5 Million Reduction in Shares Outstanding

mCig Inc. MCIG , Player’s Network, Inc. (PNTV ) Complete Phase 1 Construction for Production Facility

|Chart | Calendar   | TRADE NOW | mCig 

mCig, Inc. and Players Network, Inc. Announces Completion of Phase 1 Construction for Green Leaf Farms Cultivation and Production Facility in North Las Vegas

BUZ INVESTORS PRESS RELEASE  MCIG , Player’s Network  mCig Inc., ( OTCQB : MCIG ), a leading distributor of innovative products, technologies, and services for the global medical cannabis industry and Player’s Network, Inc. ( OTCQB : PNTV ), a diversified holding company operating in media and marijuana, today announce the Phase 1 completion of Green Leaf Farms Holdings, facility in North Las Vegas.
Green Leaf Farms Holdings, LLC (Green Leaf), a subsidiary of PNTV, contracted mCig to develop and buildout their 27,000 sq. ft. facility in North Las Vegas. mCig completed the first Phase of development which included two vegetation and flower rooms, an extraction lab and all the needed infrastructure to support the facility. In addition, mCig worked with the City of North Las Vegas and the State of Nevada to ensure Green Leaf was 100% compliant. mCig has already completed the design, structural engineering and technical specifications for the remaining build out of the full 27,000 sq. ft. facility.

In addition to the completion of Phase 1, mCig is already nearing the completion of Phase 2 out of 3 total phases. Phase 2 is expected to complete in approx. 6 weeks which will add an additional 7,000 sq. ft. of cultivation to the facility.

MCIG , Player’s Network

PNTV Chief Executive Officer, Mark Bradley said, “Working with multiple government agencies and being fully compliant with so many rules and regulations has been very challenging! Working with mCig’s management, specifically Ron Sassano and Robert Kressa, has made this process so much easier due to their invaluable industry expertise, know-how and experience in both construction and marijuana facility design.”

“Green Leaf’s facility is a state-of-the-art marijuana facility,” said Paul Rosenberg, mCig’s Chief Executive Officer. He continued, “The building has an amazing footprint with high ceilings and plenty of additional land that allows us to fully customize around optimizing growing marijuana and creating efficiencies with an ideal operation. We are looking forward to completing the next phase of development.”

About Medical Cannabis Innovations Group ( OTCQB : MCIG )

Headquartered in Henderson, Nevada, mCig, Inc. ( OTCQB : MCIG ) is a diversified company servicing the legal cannabis, hemp and CBD markets via its lifestyle brands. mCig, Inc. is committed to being the leading distributor of technology, products, and services to fit the needs of a rapidly expanding industry. mCig, Inc. has transitioned from a vaporizer manufacturer to industry leading large scale, full service cannabis cultivation construction company with its Grow Contractors division currently operating in the rapidly expanding Nevada market.

mCig, Inc. also employs a world renowned tech team and has recently entered the tech space to satisfy its evolving role in technology and in keeping it’s growing following up to speed.

The company looks forward to growing its core competencies to service the ancillary legal Cannabis, Hemp and CBD markets, with broader expansion to take place once federal laws change. With over seventy five years of experience combined between the key players that make up the Cannabis Grow Contractors Division, mCig Inc. is proud to work with Cannabis Industry leaders and provide broad and rounded solutions for legal growers nationwide.

About Player’s Network, Inc. (PNTV)

Player’s Network is a diversified company operating in media and cannabis markets. PNTV owns approximately 85% of Green Leaf Farms Holdings, LLC (Green Leaf Farms), which holds cultivation and production license(s) awarded by the state of Nevada. The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. is developing the ultimate resource for the marijuana lifestyle within our media operations.

For more information please visit
Please visit our Investor Relations site
Sign up for PNTV investor alerts:

About Green Leaf Farms Holding, LLC

Green Leaf Holdings, LLC (Green Leaf Farms) produces medical and recreational cannabis products. Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 27,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.

Business Description

Industry: Tobacco Products » Tobacco    NAICS: 312230    SIC: 2111
Traded in other countries: M06.Germany,
Headquarter Location: USA

mCig Inc is a technology company. It is engaged in manufacturing and retailing of loose-leaf Ecig.

mCig Inc was incorporated in the State of Nevada on December 30, 2010 originally under the name Lifetech Industries, Inc. Effective August 2, 2013, the name was changed from Lifetech Industries, Inc. to mCig, Inc. The Company manufactures and retails the mCig, an affordable loose-leaf eCig. It provides a smoking experience by heating plant material, waxes, and oils delivering, in the Company’s opinion, a smoother inhalation experience. It operates in two two long-term secular trends: The decriminalization and legalization of marijuana for medicinal or recreational purposes – legalizing medicinal and recreational marijuana usage is steadily on the rise not only domestically but also internationally, The adoption of electronic vaporizing cigarettes (commonly known as “eCigs”), as smokers move away from traditional cigarettes onto e-cigarettes. Smoking tobacco causes numerous health problems, including disease and death. It competes with other sellers of electronic cigarettes, notably Lorillard, Inc., Altria Group, Inc. and Reynolds American Inc.


Like up on FACEBOOK


Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

BUZINVESTORS Introducing Simplicity to Cryptocurrencies – The Singapore-based ‘Crypto-One-Stop-Solution platform’ (COSS) has announced the beta release of its cryptocurrency services. The cryptocurrency

COSS.IO: Introducing Simplicity to Cryptocurrencies Enters Beta Phase

COSS.IO platform’s beta launch includes e-wallets, professional exchange and merchant platform services, brings cryptocurrency to all.

BUZINVESTORS Introducing Simplicity to Cryptocurrencies – The Singapore-based ‘Crypto-One-Stop-Solution platform’ <span data-recalc-dims=(COSS) has announced the beta release of its cryptocurrency services. The cryptocurrency " width="300" height="180" srcset=" 300w, 768w, 1000w" sizes="(max-width: 300px) 100vw, 300px" />

BUZINVESTORS Introducing Simplicity to Cryptocurrencies – The Singapore-based ‘Crypto-One-Stop-Solution platform’ (COSS) has announced the beta release of its cryptocurrency services. The cryptocurrency solutions platform brings together a dedicated wallet service, exchange, and a merchant platform upon which cryptocurrency enthusiasts and investors can interact, trade currencies and ideas.

The COSS project is developed by an international team headquartered in Singapore under C.O.S.S. PTE LTD license and guided by the company’s CEO Rune Evensen. The COSS initiative was first presented by Rune to the MIT Fintech course committee in early 2016, and it’s due to the continued support and belief of the participants of the course that such a massive project was able to come to fruition.

After the course, the COSS team devised a detailed strategy, highlighting plans to initiate the project by December 2016, to be followed shortly by the Beta phase in early Q1, 2017. COSS has been dubbed ‘the living project’ by its developers and is designed with the intention of creating a self-sustaining ecosystem that can continue supporting more and more start-ups over time until the end of the internet itself.


Introducing Simplicity to Cryptocurrencies 

In February 2017, the platform published its whitepaper on COSS.IO homepage, outlining the technical specifications of the platform. COSS developers, learning from the past errors of Bitcoin developers have focused on the security of the platform, implementing the more consolidated, cryptocurrency-agnostic platform for the benefit of crypto-community and others.

The main purpose of COSS is to create a single, user-friendly ecosystem suitable for mass adoption among non-technical users, or individuals new to the Industry. The platform enables a system that combines cryptocurrency and fiat services, made available to customers over a single registered account within the platform.

The CEO of COSS Rune Evensen sharing thoughts about the platform’s focus said,

“Redefining simplicity has been on our mind since day one, and we truly believe that COSS can make it a lot simpler for any average Joe out there to enter the world of cryptocurrencies and blockchain-related products and services.”

The beta soft launch version of COSS platform has enabled its exchange feature with fully operational payment gateway (POS) system. Interested users can now test the exchange, merchant list and point-of-sale to get a feel of COSS platform and realize its vision. The cryptocurrency platform’s other main features, including a crowdfunding tool, an ICO platform, third-party plugins, market cap and coin overviews, a blockchain forum, remittance and payment gateway are all just around the corner awaiting implementation.

The native currency of the COSS platform, VEROS is implemented as an Ethereum smart contract, which governs the validation, distribution, value and the ownership of the tokens. Apart from VEROS, the platform will support most widely-used cryptocurrencies, enabling customers to convert them into fiat via the COSS exchange service. A lot more features will be added to the platform during the next phase of development.

On the event of COSS platform’s beta launch, Rune personally thanking every developer, community member, and supporter said,

“I would like to personally thank all the involved parties that have contributed endless hours to this project. Although we are just getting started, it is a huge MILESTONE for us to finally go live.”


COSS stands for Crypto-One-Stop-Solution and represents a platform which encompasses all features of a digital economic system based on cryptocurrency. The COSS system consists of website payments, seller tools, a marketplace, financial module, e-wallets, coin facilities and a mobile platform. The platform unifies the most popular crypto and fiat currency services, e.g. exchanges, payrolls, wallets, acquisitions and transactions.

Ebates Coupons and Cash Back

Market quotes are powered by

Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )

BUZ INVESTORS OWM Announces Second Phase - One World Minerals Inc. (CSE:OWM) (the "Company") is pleased to announce the start of a second phase exploration program on the Company's Rico Litio lithium property

$OWM Announces Second Phase Work Program

One World Minerals Inc. Announces Second Phase Work Program Including 4000 M of Drilling on Its Rico Litio Lithium Project

BUZ INVESTORS OWM Announces Second Phase - One World Minerals Inc. <span data-recalc-dims=(CSE:OWM) (the "Company") is pleased to announce the start of a second phase exploration program on the Company's Rico Litio lithium property" width="300" height="103" srcset=" 300w, 646w" sizes="(max-width: 300px) 100vw, 300px" />BUZ INVESTORS OWM Announces Second Phase One World Minerals Inc. (CSE:OWM) (the “Company”) is pleased to announce the start of a second phase exploration program on the Company’s Rico Litio lithium property located in the State of California Baja Norte, Mexico. Logistical preparations are underway with field crews on the property within three weeks and concluding with a 4000 metre (13,000 foot) drill program to be completed by the end of June 2017.

The second phase program will consist of 80 kilometres (50 miles) of surveyed grid lines in the northern portion of the property in preparation to complete a time domain electromagnetic survey. This survey will help to identify sediment formations with good permeability and porosity that may contain lithium brines. In addition, a gravity survey will be conducted over the same grid lines to identify the depths of the closed basin as well as structural features and young volcanic rocks that may contribute to the formation of the lithium brine. Historically these geophysical surveys have worked extremely well in identifying structural targets in preparation for drilling.


OWM Announces Second Phase

Coincident with the geophysical programs, an additional 500 geochemical samples will be taken to further delineate anomalous lithium.

The second phase also includes, a four thousand meter (13,000 feet) drill program to test several of the high priority targets that have coincidental anomalies that may contain brine and traps created by active faults.

A third phase program will include a pump test work program done on sections of the drill holes to test and determine the aquifer capacity; draw down flow rates, and concentrations of Lithium and potassium.

As previously reported on March 10, 2017 the Company is acquiring up to a 90% interest in the Rico Litio Property. The property covers a large closed basin (or salar) that is 291 square miles or 75,410 hectares. The Company who is the operator, will contract the exploration program to Jehcorp Inc., a private company owned by John Hiner who has over 45 years’ mineral exploration experience, including lithium and potassium properties in North and South America. A group led by John Hiner also identified the Rico Litio Property.

Doug Fulcher, President and CEO of One World commented:

“We are very pleased to moving quickly on to the next phase of work on the Rico Litio Lithium Property after such a successful first phase work program.  As well we are very fortunate to have a professional such as John Hiner coordinating and overseeing the future development of this project. His experience and knowledge of lithium and lithium projects in the Americas is so important as we further explore and advance the Rico Litio Property. The Company’s significant second phase exploration program that will be underway before the end of March 2017 and continue over the next 3 months will be highlighted by the drilling of several of the targets before the end of June 2017.”


One World Minerals Inc. announced on March 10, 2017 that it had entered into a binding letter agreement to acquire up to a 90% interest in the Rico Litio Property in Mexico (the “Property“).

The Property covers 291 square miles or 75,410 hectares over a closed basin where surface and auger samples were taken over a distance of 74 miles (120 Kilometers). The sampling work program was conducted by Lithium Investments Ltd. and returned assay results between 53 to 188 parts per million lithium in the northern part of the Property. In the southern part of the Property, samples ranged from 15 and 82 parts per million lithium, with an average value of 74 ppm lithium from 24 samples across 74 miles. It is important to note the samples were taken from surface salts and shallow auger holes and not from brines that may occur at depth.

The basin also has geological attributes to develop lithium brines, including recent tectonic and volcanic activity; many hot springs; young rhyolitic volcanic lavas; high heat flows within the region; and ash flow tuffs surrounding and within the basin.

The Property is located in the state Baja California Norte, Mexico. Ready access to the Property includes paved roads and dirt roads within the basin. There is paved access to the USA, which is 100 miles to the north. The Property is only 21 miles (35 kilometers) from San Felipe which is a well-established service center that can provide housing and mine personnel. Power is available from major power lines that cross the Property near the north end, as well as interconnected power lines from the US via Mexicali to San Felipe.

Lithium and Potassium Results of Initial Sampling Program
Wt. kg
Li ppm Sample Notes
203 1029153 0.66 0.44 24.1 rhyolitic tuff- mark 203
204 1029154 1.07 0.81 35.2 auger hole 1- 18 inch deep sample- mark 203
205 1029155 1.51 0.81 28.4 auger hole 2 – 22 inch deep sample- mark 203
206 1029156 2.58 1.37 82.0 auger hole 3- 24 inch deep sample- valley floor is rhyolitic tuff – mark 206
207 1029157 3.52 0.81 35.1 auger hole 4 – 24 inch deep sample- mark 207
207 1029158 4.84 0.7 31.1 auger hole 4 5 foot deep sample mark 207
210 1029160 1.77 0.08 5.0 spherulitic rhyolite rock chip – mark 210
211 1029161 2.03 0.32 15.2 fine grained lithic tuff- unconfrormable over spher rhy -mark 210
212 1029162 2.59 0.07 4.7 crs grained qtz eye lithic tuff – mark 213
213 1029163 1.61 0.42 19.4 fine grained qtz-mica shell bearing tuff- mark 213
214 1029164 1.69 1 53.3 auger hole 5 – 24 inch deep salar sed vfg soil – mark 214
215 1029165 2.14 1.31 66.8 auger hole 6- clayey salar sed-trc mca salt veneer on srfc- mark 215
216 1029166 1.62 0.66 69.2 auger hole 7- vfg clayey brn soil, interstitial salt in mtx – mark 216
217 1029167 2.27 0.52 33.9 auger hole 8- 24 inch deep, m-dk bn vfg slty-clayey w mca +salt-mark 217
218 1029168 2.1 1.58 132.5 auger hole 9 – m bn clay w vfg salt, tr moisture- mark 218
219 1029169 2.71 1.57 103.5 auger hole 10- hard caliche at 18inch depth, m bn fg sdy silt- mark 219
220 1029170 2.01 1.41 91.2 auger hole 11- dk bn cly slt w abun salt – mark 220
220 1029171 0.75 1 66.3 hand pick of salt concentrated at surface- mark 220
221 1029172 2.36 1.4 92.0 auger hole 12- vfg sdy silt w caliche layers – mark 221
222 1029173 2.14 1.45 95.8 auger hole 13- m bn slty qz-fld sltst – mark 222
223 1029174 1.61 1.43 90.9 auger hole 14- vfg qz-fld mica clay- mark 223
224 1029175 2.43 1.97 188.5 auger hole 15- hard salt srfc, 2 12 inch holes, mica clay- mark 224
225 1029176 2.04 1.41 159.5 auger hole 16- slty cly com salt in mtx- mark 225
225 1029177 0.78 0.92 84.3 hand pick of salt concentrate at srfc- mark 225
226 1029178 3.33 0.4 50.8 auger hole 17- tan fg slty ss +/-mca, com thn cly layers- mark 226
227 1029179 0.53 0.52 30.8 thn bedded slty vfg lakebed- mark 227
228 1029180 0.98 0.27 21.8 cross bd qz-fld bio vfg ss- mark 228

Andrea Diakow, P. Geo., a Qualified Person as defined in NI 43-101, and a consultant of OWM, has read and approved the scientific and technical disclosure as stated in this news release.

On behalf of the Board of Directors of One World Minerals Inc.

Ebates Coupons and Cash Back

Commodities ( Gold ) ( Silver ) ( Lithium )

Cara Therapeutics Inc. (NASDAQ: CARA)

$CARA Announces Positive Top-Line Data From Part A of Phase 2/3 Trial

Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus

BUZ INVESTORS Cara Therapeutics, Inc. <span data-recalc-dims=(Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus" width="300" height="168" />

BUZ INVESTORS Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced positive top-line results from Part A of its Phase 2/3 trial showing that I.V. CR845 met both primary and secondary endpoints for efficacy (reduced itching and improved quality of life, respectively) in patients with uremic pruritus (UP) with statistical significance. UP is an intractable and debilitating systemic itch condition with a high prevalence in patients with chronic kidney disease (CKD), for which there are no approved therapies in the United States.


Cara Therapeutics

“We are extremely pleased with these results, where I.V. CR845 demonstrated sustained clinical and quality of life benefits in dialysis patients suffering from UP and supports the viability of this therapeutic approach for the long-term treatment of this unmet medical need,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. “As a next step, we plan to meet with the FDA to finalize the trial design of Part B of this Phase 2/3 study and to initiate patient recruitment later this year.”

“These exciting results underscore I.V. CR845’s potential, if successfully developed, to become an approved therapy in the U.S. for CKD patients suffering from UP,” said Gil Yosipovitch, M.D., Professor of Dermatology, Miller School of Medicine, and Director of the Miami Itch Center at the University of Miami. “There is an unmet medical need for an effective long-term therapy for treating this intractable pruritus and providing meaningful improvement in the quality of life of these patients under dialysis treatment.”

“This study demonstrated encouraging, statistically significant improvements across quality of life measures for hemodialysis patients with this condition,” said Mark Unruh, M.D., Chair of the Department of Internal Medicine at the University of New Mexico School of Medicine. “Importantly, these improvements persisted for the entire eight-week treatment period, with the anti-itch effect apparently sustained over time, suggesting that CR845 has the potential to be an effective treatment for this difficult condition, if successfully developed and approved.”

I.V. CR845 Phase 2/3 UP Trial Design and Top-line Results

Part A of the Phase 2/3 UP trial was a randomized, double-blind, placebo-controlled trial of three doses of I.V. CR845 (0.5 ug/kg, 1.0 ug/kg, and 1.5 ug/kg) administered three times per week after dialysis over an eight-week treatment period in 174 patients with moderate-to-severe UP.

The primary endpoint was the change from baseline of the mean worst itching score for week eight (days 51-57) based on a validated 0-10 Numeric Rating Scale (NRS). Patients receiving I.V. CR845 experienced a 68 percent greater reduction from baseline in worst itch scores than those receiving placebo (p-value<0.0019).

The secondary endpoint focused on quality of life measures associated with pruritus using the Skindex-10 score, a validated self-assessment scale with higher scores indicating worse quality of life. Patients receiving I.V. CR845 experienced a 100 percent greater reduction from baseline in the average total Skindex-10 score at week eight than those receiving placebo (p-value<0.0007). The total average Skindex-10 score reflected statistically significant reductions in each of the three Skindex-10 domains; disease (p-value=0.0001), mood/emotional distress (p-value=0.01), and social functioning (p-value=0.009).

Overall, I.V. CR845 was well tolerated over the eight-week treatment period and the unblinded Drug Safety Monitoring Board did not report any significant drug-related events during the course of the trial. The most common adverse events were transient paresthesia (primarily mid-facial tingling or numbness) and dizziness, as reported in previous clinical studies of I.V. CR845.

Cara plans to meet with the U.S. Food and Drug Administration (FDA) for an end-of-Phase 2 meeting to review the results to determine an optimal dose to take into Part B of this Phase 2/3 study, and define the broader path towards approval. Pending discussions with the FDA, Part B of the study is intended to be a randomized, double-blind, placebo-controlled trial of I.V. CR845 administered three times per week after dialysis over a 12-week treatment period in up to 240 patients with moderate-to-severe UP.

Conference Call

Cara management will host a conference call today at 8:30 a.m. ET to discuss the trial results and next steps for the program.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 97080265. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Uremic Pruritus

Uremic pruritus (UP) is an intractable systemic itch condition that occurs with the greatest frequency and intensity in chronic kidney disease (CKD) patients under hemodialysis (HD) and peritoneal dialysis; however, pruritus has also been reported in CKD patients who are not yet on dialysis. Aggregate, longitudinal, multi-country studies estimate the weighted prevalence of UP to be approximately 40 percent of patients with end-stage renal disease (ESRD), with approximately 24 percent of patients reporting severe pruritus. Similarly, the majority of dialysis patients (approximately 60-70 percent) report pruritus, with 30 to 40 percent reporting moderate or severe pruritus. Recent data from the ITCH National Registry Study showed that among those with pruritus, 59 percent had experienced symptoms daily or nearly daily for more than a year. Given its association with CKD/ESRD, most afflicted patients will continue to have symptoms for months or years with currently employed anti-pruritic treatments, such as anti-histamines and corticosteroids, which are unable to provide consistent adequate relief. Moderate-to-severe chronic pruritus has repeatedly been shown to directly decrease quality of life, contribute to symptoms that impair quality of life (such as poor sleep quality), and is associated with depression. UP is also an independent predictor of mortality among HD patients, mainly related to increased risk of inflammation and infections.

About CR845

CR845 is a peripherally-acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in pain intensity and opioid-related side effects. In more than 600 subjects dosed to date, I.V. CR845 was found to be well-tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally-acting (CNS-active) kappa opioid receptor agonists, and lacking the respiratory depression and abuse liability of mu opioid receptor agonists. Top-line data from a Phase 2b trial of CR845 in chronic pain associated with osteoarthritis and a conditional power analysis from an adaptive Phase 3 trial in postoperative pain are expected in the second quarter of 2017.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body’s peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Ebates Coupons and Cash Back

Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )

Buz Investors Applied Materials, Inc. (NASDAQ:AMAT) reported fiscal first-quarter results Wednesday and the upbeat results proved once again that the upward march of AMAT stock is not going to stop any time soon.

AMAT Stock Looking At A High Growth Phase

Applied Materials Stock to Fly High on Secular Tailwinds

Buz Investors Applied Materials, Inc. <span data-recalc-dims=(NASDAQ:AMAT) reported fiscal first-quarter results Wednesday and the upbeat results proved once again that the upward march of AMAT stock is not going to stop any time soon. " width="300" height="200" srcset=" 300w, 720w" sizes="(max-width: 300px) 100vw, 300px" />

Buz Investors Applied Materials, Inc. (NASDAQ:AMAT) reported fiscal first-quarter results Wednesday and the upbeat results proved once again that the upward march of AMAT stock is not going to stop any time soon. The business growth would be lifted by strong tailwinds in areas like the Internet of Things (IoT), cloud computing, and autonomous driving, thereby providing a lot of room for Applied Materials stock to grow.

The leading semiconductor equipment maker delivered record earnings per share (EPS), with adjusted EPS coming at $0.67 per share. Applied generated record new orders worth $4.24 billion, which was an increase of 86% year-over-year. The Q1 2017 net sales were at $3.28 billion, up 45% year-over-year. Further, the company expects to post record revenue as well as EPS in Q2 of fiscal 2017. (Source: “Applied Materials Delivers Record Earnings Per Share,” Applied Materials, Inc., February 15, 2017.)

Other Stories Buz Traders Follow

Applied Materials

Rumors that Apple will opt for OLED displays in its next iPhone have been making the rounds for quite a while, and the company stands to benefit immensely from this development. Applied Materials has already received a number of orders for its OLED display equipment, and it looks like Applied Materials stock has more room to run.

CEO Gary Dickerson says that the demand for advanced technology and chips will only keep rising, as the smartphone race gets more intense. In an interview with CNBC on Thursday, Dickerson stated that the company had never been in a better position.

Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )

Electronic Government as a Service — eGaaS Enters Beta Testing Phase

Electronic Government as a Service — eGaaS Enters Beta Testing Phase

Electronic Government as a Service — eGaaS Enters Beta Testing Phase

The blockchain platform for world governments has started beta testing its platform amidst the ongoing ICO.

Electronic Government as a Service — eGaaS Enters Beta Testing Phase

November 20, 2016 – Electronic Government as a Service — eGaaS, an international blockchain platform for organizing the economic, state and social activities for citizens and their communities based on smart law and smart contracts has entered the testing phase. The platform is designed to make the migration of government and community functions to blockchain easier. eGaaS does it by implementing four basic functions — financial system, registry structure, smart contract algorithm and smart law formation & execution mechanism.

The features of eGaaS are sufficient to efficiently transfer most types of government, legislative and business activities onto blockchain. The platform is the first of its kind to implement a mechanism to frame and execute smart laws. These smart laws are algorithms describing the rules and conditions regulating the execution of state laws. The credibility of smart laws is confirmed by the representatives of legislative bodies using digital signatures. Smart laws are responsible for regulating the creation and execution of smart contracts. They automatically regulate the relationship between individuals and organizations in all areas of state activity, ranging from civil registration to tax remissions.

Being a blockchain platform with the mechanism for creation and execution of smart contracts and smart laws, eGaaS can be used even before governments come onboard. eGaaS can be successfully used to create a variety of financial, business and social applications such as payment systems, stock exchanges, insurance and credit organizations, accounting and management systems for all fields — from commerce to medicine. The eGaaS platform is a handy tool for organizing communities’ activities. It makes allowance for creating rules of relations between their members and conduct voting.

eGaaS emphasizes that the common international blockchain is not a political or publicity stunt, but a technical and economic necessity. Blockchain can be a reliable and effective tool only if all the data used in preparing smart contracts, including state laws, are located in the same information space. A modern global economy requires that such a space should be global in nature.

By combining the financial system, registry structure, smart contract and smart law mechanisms into a common blockchain platform, eGaaS serves as anefficient tool for the government, legislative bodies, business, and citizens, which can be used to manage any activity. It eliminates the need for multiple intermediaries, regulatory authorities, and document circulation.

About eGaaS

eGaaS is an international blockchain platform implementing four basic functions needed for efficient transfer of most types of government, legislative bodies and business activities onto blockchain.

Learn more about eGaaS at –

Vertex Pharmaceuticals Incorporated (VRTX) - NASDAQ

Vertex Provides Update on Ongoing Phase 3 Program for VX-661

Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis

-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the study-

-Enrollment complete in Phase 3 study in people with two copies of the F508del mutation-

-Enrollment expected to be completed in September in Phase 3 study in people with one F508del mutation and one residual function mutation-



Vertex Provides Update on Ongoing Phase 3 Program for VX-661

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its ongoing Phase 3 development program of its investigational compound VX-661 in combination with ivacaftor, which includes four studies that together are expected to enroll more than 1,000 people with cystic fibrosis (CF). Based on a planned interim futility analysis conducted by the study’s independent Data Safety Monitoring Board (DSMB), Vertex plans to stop the study of VX-661 and ivacaftor in people with one copy of the F508del mutation and one copy of a mutation that results in minimal CFTR protein function (F508del het/min). There were no safety concerns noted in the DSMB’s review of the data. Vertex also today announced that enrollment is now complete in the study of VX-661 and ivacaftor in people with two copies of the F508del mutation (F508del homozygous) and that the company expects to complete enrollment in the study of people with one copy of the F508del mutation and one copy of a residual function mutation in September.

“While we recognize that people with CF with minimal function mutations have a form of the disease that is particularly difficult to treat, we believed it was important to evaluate whether a dual combination of VX-661 and ivacaftor could provide some benefit to these patients given they do not today have a medicine to treat the cause of their disease,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. “These results suggest that a triple combination regimen may provide this group of people with CF the best chance at obtaining a meaningful benefit and we look forward to beginning the first study of a next-generation corrector together with VX-661 and ivacaftor in this group of patients later this year, pending data from our ongoing Phase 1 studies in healthy volunteers.”

The VX-661 Phase 3 program includes four Phase 3 studies in multiple different groups of people with CF who have at least one copy of the F508del mutation. The studies are evaluating VX-661 dosed as 100 mg once daily (QD) in combination with ivacaftor dosed as 150 mg every 12 hours (q12h). These studies include people with CF with the following mutations:

  • Two Copies of the F508del Mutation: In August, Vertex completed enrollment in a study evaluating 24 weeks of treatment with VX-661 in combination with ivacaftor in approximately 500 people with CF who have two copies of the F508del mutation. Data from this study are expected in the first half of 2017.
  • One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function: In September, Vertex expects to complete enrollment in a study evaluating VX-661 in combination with ivacaftor in approximately 200 people with residual function mutations. The crossover study includes two 8-week dosing periods, separated by an 8-week washout period. The study includes an arm of ivacaftor monotherapy, in addition to an arm evaluating VX-661 in combination with ivacaftor and a placebo arm. Data from this study are expected in the first half of 2017.
  • One Copy of the F508del Mutation and a Second Mutation that Results in a Gating Defect in the CFTR Protein: Enrollment is ongoing in a study designed to evaluate VX-661 in combination with ivacaftor in people with gating mutations that have been shown to be responsive to ivacaftor alone. The study is expected to enroll approximately 200 patients and is evaluating 8 weeks of treatment with VX-661 in combination with ivacaftor. Enrollment is expected to complete in late 2016 or early 2017.
  • One Copy of the F508del Mutation and a Second Mutation that Results in Minimal CFTR Function: In April, Vertex completed enrollment of approximately 150 people in Part A of a two-part study evaluating people with mutations that result in minimal CFTR function. A planned interim futility analysis was conducted by the study’s independent DSMB after at least 8 weeks of dosing to determine whether to stop the study or to continue the study and initiate enrollment in Part B. The analysis showed that the combination of VX-661 and ivacaftor did not result in a pre-specified improvement in lung function. The DSMB recommended that Vertex stop the study and not initiate enrollment in Part B. There were no safety concerns noted in the DSMB’s review of the data. Vertex plans to close this study based on the recommendation of the DSMB, and patients from Part A of the study who enrolled in the long-term extension study will be transitioned off the combination of VX-661 and ivacaftor.

Vertex plans to submit a New Drug Application (NDA) to the FDA for VX-661 in combination with ivacaftor in the second half of 2017, pending data from the Phase 3 program. The NDA is expected to include data from the study in people with minimal function mutations.

About Cystic Fibrosis

Cystic fibrosis is a rare, life-shortening genetic disease affecting approximately 75,000 people in North America, Europe and Australia. Today, the median predicted age of survival for a person with CF is between 34 and 47 years, but the median age of death remains in the mid-20s.

CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are more than 1,900 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic, or genotyping test, lead to CF by creating non-working or too few CFTR protein at the cell surface. The defective function or absence of CFTR proteins in people with CF results in poor flow of salt and water into and out of the cell in a number of organs, including the lungs. This leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage.